<DOC>
	<DOCNO>NCT01368588</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Androgen deprivation therapy may stop adrenal gland make androgen . Radiation therapy use high-energy x-ray kill tumor cell . PURPOSE : This randomized phase III trial study androgen-deprivation therapy radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Androgen-Deprivation Therapy Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Demonstrate prophylactic , neoadjuvant , androgen-deprivation therapy ( NADT ) whole-pelvic radiation therapy ( WPRT ) result improvement overall survival ( OS ) patient `` unfavorable '' intermediate-risk `` favorable '' high-risk prostate cancer compare NADT high-dose prostate ( P ) seminal vesicle ( SV ) radiation therapy ( RT ) use intensity-modulated RT ( IMRT ) external-beam RT ( EBRT ) high-dose rate ( HDR ) permanent prostate ( radioactive seed ) implant ( PPI ) boost . Secondary - Demonstrate prophylactic WPRT improve biochemical control . - Determine distant metastasis ( DM ) -free survival . - Determine cause-specific survival ( CSS ) . - Compare acute late treatment-adverse event patient receive NADT WPRT versus NADT , P , SV RT . - Determine whether health-related quality life ( HRQOL ) , measure Expanded Prostate Cancer Index Composite ( EPIC ) , significantly worsen increase aggressiveness treatment ( i.e. , Arm 2 , NADT + WPRT ) . - Determine whether aggressive treatment ( Arm 2 , NADT + WPRT ) associate great increase fatigue ( PROMIS Fatigue Short Form ) baseline last week treatment , great increase circulate inflammatory marker ( IL-1 , IL-1ra , IL-6 , tumor necrosis factor ( TNF ) -alpha , C-reactive protein ) . - Demonstrate incremental gain OS CSS aggressive therapy outweigh detriment primary generic domain HRQOL ( i.e. , mobility , self-care , usual activity , pain/discomfort , anxiety/depression ) . - Determine whether change fatigue baseline next three time point ( week prior RT , last week treatment , 3 month treatment ) associate change circulate cytokine , mood , sleep , daily activity across time point . - Collect paraffin-embedded tissue block , plasma , whole blood , urine plan future translational research analysis . OUTLINE : This multicenter study . Patients stratify accord moderate- high-risk group list Disease Characteristics abstract , type radiotherapy boost ( IMRT vs brachytherapy [ Low-dose rate ( LDR ) use PPI HDR ] ) , duration androgen-deprivation therapy ( short-term [ 6 month ] vs long-term [ 32 month ] ) . Patients randomize 1 2 treatment arm . All patient receive neoadjuvant androgen-deprivation therapy comprise bicalutamide orally ( PO ) daily flutamide PO thrice daily 6 month , luteinizing hormone-releasing hormone ( LHRH ) agonist/antagonist therapy comprise leuprolide acetate , goserelin acetate , buserelin , triptorelin , degarelix subcutaneously ( SC ) intramuscularly ( IM ) every 1 3 month begin 2 month prior radiotherapy continue 6 32 month . Radiotherapy begin within 8 week begin LHRH agonist/antagonist injection . - Arm I : Patients undergo high-dose radiotherapy prostate seminal vesicle use intensity-modulated radiotherapy ( IMRT ) * 3D-conformal radiation therapy ( 3D-CRT ) * daily , 5 day week , approximately 9 week . Patients may also undergo permanent prostate implant ( PPI ) brachytherapy high-dose rate brachytherapy ( iodine I 125 palladium Pd 103 may use radioisotope ) . - Arm II : Patients undergo whole-pelvic radiotherapy ( WPRT ) * ( 3D-CRT IMRT ) daily , 5 day week , approximately 9 week . Patients may also undergo brachytherapy arm I . NOTE : * Patients undergo brachytherapy implant receive 5 week IMRT , 3D-CRT , WPRT . Patients may undergo blood urine sample collection correlative study . Primary tumor tissue sample may also collect . Patients may complete Expanded Prostate Cancer Index Composite ( EPIC ) , PROMIS-Fatigue Short Form , EuroQol ( EQ-5D ) quality-of-life ( QOL ) questionnaires baseline periodically treatment . Patients participate QOL portion study must also agree periodic blood collection . After completion study therapy , patient follow every 3 month 1 year , every 6 month 3 year , yearly thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically ( histologically cytologically ) proven diagnosis prostatic adenocarcinoma within 180 day registration moderate highrisk recurrence determine one follow combination : Gleason score 710 + T1cT2b ( palpation ) + prostatespecific antigen ( PSA ) &lt; 50 ng/mL ( include intermediate highrisk patient ) Gleason score 6 + T2cT4 ( palpation ) + PSA &lt; 50 ng/mL OR Gleason score 6 + &gt; = 50 % ( positive ) biopsy + PSA &lt; 50 ng/ml Gleason score 6 + T1cT2b ( palpation ) + PSA &gt; 20 ng/mL Patients previously diagnose low risk prostate cancer undergo active surveillance rebiopsied find unfavorable intermediate risk disease favorable high risk disease accord protocol criterion eligible enrollment within 180 day repeat biopsy procedure . History and/or physical examination ( include minimum digital rectal examination prostate examination skeletal system abdomen ) within 90 day prior registration Clinically negative lymph node establish image ( pelvic and/or abdominal CT MR ) , ( nodal sampling , dissection ) within 90 day prior registration Patients lymph nodes equivocal questionable image eligible node ≤ 1.5 cm Patients status post negative lymph node dissection eligible No evidence bone metastasis ( M0 ) bone scan within 120 day prior registration ( Na F PET/CT acceptable substitute ) Equivocal bone scan finding allow plain film ( CT MRI ) negative metastasis Baseline serum PSA value perform FDAapproved assay ( e.g. , Abbott , Hybritech ) within 120 day prior registration Study entry PSA obtain follow time frame : Tenday period follow prostate biopsy Following initiation hormonal therapy Within 30 day discontinuation finasteride Within 90 day discontinuation dutasteride PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute neutrophil count ( ANC ) ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ( Hgb ) ≥ 8.0 g/dL ( transfusion intervention achieve Hgb ≥ 8.0 g/dL acceptable ) No prior invasive ( except nonmelanoma skin cancer ) malignancy unless diseasefree minimum 3 year ( 1,095 day ) pelvis E.g. , carcinoma situ oral cavity permissible ; however , patient prior history bladder cancer allow No prior hematological ( e.g. , leukemia , lymphoma , myeloma ) malignancy No previous radical surgery ( prostatectomy ) cryosurgery prostate cancer No previous pelvic irradiation , prostate brachytherapy bilateral orchiectomy No previous hormonal therapy , LHRH agonists ( e.g. , leuprolide , goserelin , buserelin , triptorelin ) LHRH antagonist ( e.g . degarelix ) , antiandrogens ( e.g. , flutamide , bicalutamide , cyproterone acetate ) , estrogens ( e.g. , DES ) , surgical castration ( orchiectomy ) Prior pharmacologic androgen ablation prostate cancer allow onset androgen ablation ( LHRH agonist oral antiandrogen ) ≤ 45 day prior date registration . No severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Hepatic insufficiency result clinical jaundice and/or coagulation defect severe liver dysfunction Acquired immune deficiency syndrome ( AIDS ) base upon current Centers Disease Control ( CDC ) definition Protocolspecific requirement may also exclude immunocompromised patient HIV test require entry protocol No patient sexually active willing/able use medically acceptable form contraception No prior allergic reaction hormone involve protocol PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radical surgery ( prostatectomy ) cryosurgery prostate cancer No prior pelvic irradiation , prostate brachytherapy , bilateral orchiectomy No prior hormonal therapy , luteinizing hormonereleasing hormone ( LHRH ) agonists ( e.g. , leuprolide , goserelin , buserelin , triptorelin ) LHRH antagonist ( e.g. , degarelix ) , antiandrogens ( e.g. , flutamide , bicalutamide , cyproterone acetate ) , estrogens ( e.g. , diethylstilbestrol ( DES ) ) , surgical castration ( orchiectomy ) No prior pharmacologic androgen ablation prostate cancer unless onset androgen ablation ≤ 45 day prior date registration No finasteride within 30 day prior registration No dutasteride dutasteride/tamsulosin ( Jalyn ) within 90 day prior registration No prior concurrent cytotoxic chemotherapy prostate cancer Prior chemotherapy different cancer allowable No prior radiotherapy , include brachytherapy , region study cancer would result overlap radiation therapy field</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>